Home Newsfeeds Barclays Downgrades Ingredion to Equal-Weight, Announces $110 Price Target

Barclays Downgrades Ingredion to Equal-Weight, Announces $110 Price Target

Barclays analyst Benjamin Theurer downgrades Ingredion (NYSE:INGR) from Overweight to Equal-Weight and announces $110 price target.

January 23, 2023

1 minute read

Barclays analyst Benjamin Theurer downgrades Ingredion (NYSE:INGR) from Overweight to Equal-Weight and announces $110 price target.

Analyst Expectations for Willis Towers Watson’s Future

January 18, 3:01 PM

Over the past 3 months, 10 analysts have published their opinion on Willis Towers Watson (NASDAQ:WTW) stock. These…

September 11, 7:42 AM

Updated results from DESTINY-Lung01 Phase II trial demonstrate continued durable activity across patient subtypes

January 12, 2:17 AM

The Nasdaq reached its highest point on March 10, 2000, at 5,132.52. Unfortunately, things took a turn for the worse, and the bubble burst.

April 9, 9:00 AM

In the preceding three months, 8 analysts have released ratings for Alpine Immune Sciences (NASDAQ:ALPN), presenting a wide…